China
Africa
Explore chapters and articles related to this topic
Analgesics during Pregnancy
Published in “Bert” Bertis Britt Little, Drugs and Pregnancy, 2022
Phenylbutazone is an NSAID with analgesic, antipyretic, and anti-inflammatory actions commonly used to treat women with arthritic conditions (rheumatoid arthritis, degenerative joint disease). No scientific studies are published regarding the safety or efficacy of this medication in pregnant women. Unpublished data had 27 infants who were exposed to phenylbutazone during the first trimester, and two major birth defects were found (Rosa, personal communication, cited in Briggs et al., 2017). Some prostaglandin synthetase inhibitors are associated with premature closure of the ductus arteriosus in the newborn (Csaba et al., 1978; Levin et al., 1978). Theoretically, phenylbutazone may be associated with premature closure of ductus arteriosus because of known pharmacologic activity of the drug, and known effects of that pharmacologic effect. No reports of this association have been published to date.
Monographs of Topical Drugs that Have Caused Contact Allergy/Allergic Contact Dermatitis
Published in Anton C. de Groot, Monographs in Contact Allergy, 2021
Phenylbutazone is a synthetic pyrazolone derivative and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic, and analgesic activities. Phenylbutazone was formerly used for the treatment of backache, ankylosing spondylitis, rheumatoid arthritis, and reactive arthritis. Because of serious systemic side effects and cutaneous adverse drug reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis, it is probably hardly used anymore, except for therapy-resistant ankylosing spondylitis. It does, however, still have applications in veterinary medicine (1). Topical use was formerly recommended for superficial phlebitis and some inflammatory diseases in the muscles and connective tissues (16).
Unexplained Fever In Hematologic Disorders Section 1. Benign Hematologic Disorders
Published in Benedict Isaac, Serge Kernbaum, Michael Burke, Unexplained Fever, 2019
Chemotherapeutic agents, irradiation, and chloramphenicol cause damage to the hematopoietic system in a predictable and dose-related way. They usually cause aplastic anemia. With other drugs (phenothiazines, antithyroid drugs, phenylbutazone, sulfonamides, etc.) the effect is idiosyncratic, based on a specific genetic susceptibility. Neutrophil destruction may be secondary to an immune mechanism (drug-hapten-antibody interaction). Phenylbutazone and aminopyrine exert their effect by such a mechanism. In some cases more than one mechanism may be involved in the induction of neutropenia. Drug-induced neutropenia can be mild or severe and, at times, irreversible.
Recent updates in curcumin delivery
Published in Journal of Liposome Research, 2023
Mohammad A. Obeid, Manal Alsaadi, Alaa A. Aljabali
Since curcumin acts as an inflammatory mediator, several publications and clinical trials have investigated the potential use of curcumin in the treatment of arthritis, which is a chronic disease characterised by dysregulation of inflammatory cytokines such as interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF), in addition to many chemokines and inflammatory enzymes. This will result in severe joint inflammation resulting from that with the subsequent joint damage and disability (Salehi et al. 2019). In this regard, the clinical study of the curcumin-treated done by Deodhar et al. showed comparable results between the group receiving curcumin with the group receiving the non-steroidal anti-inflammatory agent phenylbutazone regarding the disease signs and symptoms such as the morning stiffness and joint swelling (Dcodhar et al. 2013). In another study, diclofenac sodium was reported to have better anti-inflammatory effects when administered to patients with rheumatoid arthritis in combination with curcumin, and the group that received this combination showed better improvement in disease scores such as the American College of Rheumatology (ACR) score and the Disease Activity Score (DAS) compared to the groups that received either drugs alone (Chandran and Goel 2012).
Repeated dose of meloxicam induces genotoxicity and histopathological changes in cardiac tissue of mice
Published in Drug and Chemical Toxicology, 2022
Juliana Cyrillo Guimarães da Silva, Eliane Dallegrave, Gabriela Zimmermann Prado Rodrigues, Cassiana Bigolin, Taís Morgana Schoffen de Oliveira Neumann, Andriéli Carolina Schuster, Juliana Machado Kayser, Luciane Beatris Mentges Staudt, Melina Floriano Moraes, Débora Graziela Farias, Gabriela Schiling, Juliana Raquel Raasch, Magda Susana Perassolo, Luciano Basso da Silva, Günther Gehlen, Andresa Heemann Betti
Whereas that NSAIDs are drugs used for pathological conditions that often require long-term administration, these drugs may also cause genotoxic and carcinogenic effects (Ahmad et al.2018). Studies on the genotoxic potential of NSAIDs are limited; however, Tardieu et al. (2000) reported that nimesulide induced a significant increase in chromosome aberrations in vivo and in bone marrow cells. Recently, Ahmad et al. (2018) reported that naproxen induced the increase of micronucleus formation and DNA damage in Wistar rat cells. Abdel-Daim et al. (2018) also reported the effect of diclofenac sodium on potentiating tulathromycin-induced cardiotoxicity. In addition, a review study classified some NSAIDs as carcinogenic (phenazopyridine and phenylbutazone) and genotoxic (auranofin, dipyrone, ethenadamid, indomethacin, paracetamol and phenylbutazone) (Brambilla and Martelli 2009); and Arantes-Rodrigues et al. (2013) verified an increase in DNA damage on bladder-cancer cell lines treated with meloxicam (600 µM).
Ocular nonsteroidal inflammatory drugs: where do we stand today?
Published in Cutaneous and Ocular Toxicology, 2020
S. A. Kandarakis, P. Petrou, E. Papakonstantinou, D. Spiropoulos, A. Rapanou, I. Georgalas
In 1946, phenylbutazone, the first of the currently known category of NSAIDs, has been developed. Few years later, in the 1950–1960s, another well-known representative of the NSAIDs drug class, indomethacin, is discovered in the UK. Indomethacin establishes its analgesic and anti-pyretic efficacy, as well as its favourable safety profile, and becomes the mainstay in treating various inflammatory diseases for many years1.